Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT1A receptor agonist activity, currently being tested in phase III clinical development, with very promising results from the phase II trials, which led to the FDA designation as a breakthrough therapy for the treatment of schizophrenia [26,27,28,29,30,40,47,48,49,50,51,52]. Here, TAAR1 is linked to schizophrenia.